SPG15 Antibody | 5023

SPG15 Antibody | 5023 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: Predicted species reactivity based on immunogen sequence: Bovine: (94%)

Immunogen: SPG15 antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of human SPG15.
The immunogen is located within amino acids 1710 - 1760 of SPG15.

Research Area: Apoptosis

Tested Application: E, WB, IF

Application: SPG15 antibody can be used for detection of SPG15 by Western blot at 1 - 2 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.

Specificiy: Multiple isoforms of SPG15 are known to exist.

Positive Control 1: Cat. No. 1204 - K562 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 280 kDa
Observed: 260 kDa

Validation: N/A

Isoform: N/A

Purification: SPG15 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: SPG15 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: SPG15 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: SPG15 Antibody: SPG15, FYVE-CENT, KIAA0321, Zinc finger FYVE domain-containing protein 26, FYVE domain-containing centrosomal protein

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: SPG15 Antibody: Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders.  Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia in which mental retardation and muscle stiffness at onset are followed by slowly progressive paraparesis and cognitive deterioration. SPG15 is the second gene known to be responsible for ARHSP-TCC in the Italian population. Mutations in this gene are associated with autosomal recessive spastic paraplegia-15. SPG15 encodes a protein containing a FYVE zinc finger binding domain which is thought to target these proteins to membrane lipids through interaction with phospholipids in the membrane. SPG15 mRNA is widely distributed in human tissues, as well as in rat embryos, suggesting a possible role for this protein during embryonic development. SPG15 co-localizes partially with endoplasmic reticulum and endosome markers, suggesting a role in intracellular trafficking.